qualitative research grounded in SEC filings & market-flow signals Quant side · QuantOrb.pro ↗

BAX — Tear Sheet

BAXTER INTERNATIONAL INC

covers US session 2026-11-02 · Tear sheet created 11 days ago

AdCho Opinion

Overweight

Bottom Line

Overweight: the beat-and-raise quarter with all-segment growth supports building, but a failed bounce at the moving-average cluster, a still-bearish MACD and rates near the threshold argue for adding gradually, not chasing

Market Sentiment Summary

The run's verdict is Mildly Bullish at 6.0/10 with Low confidence, and the coverage behind it is thin.

BAX daily chart

sessions

Loading chart…

How to read this chart
  1. Top: price candles (green up, red down) with Bollinger Bands (20, 2) in dashed orange, the 50-session average in blue, the 200-session average in dashed orange, and volume bars along the bottom
  2. Middle: RSI (14), Wilder’s method, with dashed guides at 30 and 70
  3. Bottom: MACD (12, 26, 9): MACD line, dashed signal line and a green/red histogram

Prices: Yahoo Finance daily bars, split- and dividend-adjusted; indicators computed on two years of history, then the window is cut · as of latest session · Chart by TradingView Lightweight Charts™ © TradingView, Inc.

Share this tear sheet

X Facebook LinkedIn Reddit WhatsApp Email

Executive Summary

  • We read the verdict as Overweight: the reported quarter strengthens the bull case while the tape demands entry discipline
  • The constructive leg is a clean beat-and-raise with growth across every segment and a raised full-year outlook
  • Operating cash flow roughly quadrupled and operating income more than doubled over nine months, a step-change we read as genuine
  • The counterweight is the tape: the bounce failed at the moving-average cluster with MACD still below its signal
  • Money flow sits neutral-to-soft with no signal, which blocks conviction on timing rather than on direction
  • Rates are the near-term gate, with the long bond just under the watch threshold and an inflation print due
  • The balance rests on staged entry — retest or confirmed reclaim before size, never a chase

Market Sentiment

  • This run's verdict reads Mildly Bullish, scored six of ten, with low confidence — and we agree with that restraint
  • Retail tagged the print heavily bullish, but roughly half the bullish tags trace to off-target kidney-care hype
  • Skeptics cite margins, a shrinking contract book and next-year headwinds; the contract-book and headwind claims stay uncorroborated
  • Dip-buying intent was explicit and the rebound that followed supports the retail read on direction, not on timing
  • The company news lane failed all window and the global feed carried only technology items, none healthcare-relevant
  • The social capture was dominated by recruitment spam tagging the ticker in rotation baskets, leaving one substantive post
  • Money flow reads neutral with no signal, so flows have not confirmed the bullish tone
  • We weight the sentiment leg light: a thin retail sample and one hard company announcement carry the whole tilt

News

No in-window news items for this session.

Social

hacken2006

$BAX 百特国际因为业绩好，前景明显改善，前几天被错杀后，今日反弹超过5%

2026-11-02

AdCho insight: The poster reads the post-earnings sell-off as a wrongly killed dip in an otherwise improved story and notes a rebound of more than 5% into the start of November — the same retail dip-buying read the sheet's build-gradually stance credits on direction. As the only substantive capture in a spam-flooded lane, it colors the picture rather than confirming it.

Polymarket

Will no Fed rate cuts happen in 2026?
Yes 97% ($9,368,824 volume, resolves 2027-01-01, 1-week +1.0pp)

Will 11 Fed rate cuts happen in 2026?
Yes 0% ($5,331,578 volume, resolves 2027-01-01)

Will 10 Fed rate cuts happen in 2026?
Yes 0% ($4,991,758 volume, resolves 2027-01-01)

Will 9 Fed rate cuts happen in 2026?
Yes 0% ($4,315,465 volume, resolves 2027-01-01)

Will 6 Fed rate cuts happen in 2026?
Yes 0% ($4,248,444 volume, resolves 2027-01-01, 1-week +0.1pp)

Will 12 or more Fed rate cuts happen in 2026?
Yes 0% ($4,175,743 volume, resolves 2027-01-01, 1-week +0.1pp)

Live odds at run time (UTC) — macro market context, not company-specific; the rates, recession and fiscal-deadline odds every equity reads against. Not signals to act on. Topic: “Fed rate cut”.

Management Sentiment & Catalyst Highlights

  • Chief executive Andrew Hider struck a confident tone, calling the quarter strong with growth across all segments and divisions globally
  • His language centers on stabilizing the business, strengthening the balance sheet and continuous improvement — a turnaround framed as on track
  • The full-year outlook was raised, but widely quoted guide figures trace to unverified social recaps, not company-disclosed numbers
  • Organic growth excludes the kidney-care supply arrangement, so the print's growth quality is not flattered by divestiture accounting
  • The annual record supports the posture: a stated net-leverage commitment, steady dividends and the hurricane-damaged plant fully operational
  • Catalysts we can see: execution against the raised outlook into the fourth-quarter print and the institutional holdings refresh this month

Key Risk Factors

  • The primary risk is momentum: the market violently rejected a beat-and-raise on heavy volume, so sellers still lead
  • The bounce failed at the moving-average cluster on lighter volume, MACD stays below its signal and RSI never washed out
  • Margin quality is the verified bear point: a sizable sequential gross-margin contraction with below-the-line help flattering net income
  • Rates are the second leg: the Fed is hiking, inflation is re-accelerating and the long bond sits at the watch threshold
  • We corrected the ascending-lows read: the recent intraday low sits below the September low, with only closing prices holding
  • Evidence quality is the quiet risk: the news lane was down, key bear claims are unverified social recaps and the holdings snapshot is stale
  • The counterweight is real: cash-flow strength and all-segment growth against an argument from price, honored through staged entry

QuantOrb.pro Quantitative Signals

MFI (14-day)

40.47

neutral zone · None screen

qOp signal strength

NONE · 34%

quantitative screen, not a recommendation

Revenue

$2.98B

+5%

Diluted EPS

$0.57

Money-flow and momentum readings from this run's own engine outputs (QuantOrb snapshot as cited in Sources; technicals as of the covered session) — context, not signals to act on.

Not a recommendation. A quantitative screen, not a recommendation — the 13F data are a non-exhaustive quarter-end snapshot subject to a reporting lag of up to 45 days.

qOp quant view →

Sources

Facts (verifiable): SEC filings via the QuantOrb document corpus · QuantOrb money-flow & 13F datasets. Reading (AI-powered): AdCho’s synthesis via a multi-analyst AI engine.

Sheet schema adcho.tearsheet.v1 · rendered by AdCho · freshness day 11 (D11 day-0 rule, US-session dates only)